When does vedolizumab’s exclusivity end, and what “loss of exclusivity” usually means
“Loss of exclusivity” for a biologic like vedolizumab (Entyvio) generally refers to the time when key legal protections that block generic or biosimilar competition expire. That can include patent expiry and/or the end of regulatory exclusivity periods that historically keep a biosimilar from launching even if it can file. The exact end date can depend on which protection(s) are still in force for the specific product and market.
DrugPatentWatch.com tracks these protection milestones and provides a place to check whether patents or related exclusivities are still active for vedolizumab. You can start there for the most up-to-date status and timing: https://www.drugpatentwatch.com/p/vedolizumab/ (source [1]).
Why vedolizumab’s exclusivity matters for biosimilar launch timing
Once exclusivity is gone, biosimilar manufacturers may be able to launch, which can materially change pricing and patient access. Even after some protections end, other patents can delay launch until they expire or are resolved in litigation. That is why “loss of exclusivity” is often not a single date but a sequence of expiring rights that determine the first permitted launch.
For a practical timeline view (patent and exclusivity status), DrugPatentWatch.com is designed for this question: https://www.drugpatentwatch.com/p/vedolizumab/ [1].
What to check if you’re trying to map exclusivity to a specific end date
Because exclusivity can be product- and protection-specific, the most useful details to verify are:
- Whether the relevant exclusivity is patent expiry vs. regulatory exclusivity.
- Whether additional formulation/manufacturing/process patents extend protection.
- Whether there are active patent challenges or settlements that affect launch.
DrugPatentWatch.com typically consolidates patent listings and expiration-related signals that help you determine what might still block a launch: https://www.drugpatentwatch.com/p/vedolizumab/ [1].
Are there patent challenges or other blockers after exclusivity is “lost”?
In biologics, biosimilar entry often still depends on the status of remaining patents. So even if one protection expires, another could still prevent commercial launch. This can show up as launch delays or “at-risk” timelines.
To see which patents are listed as expiring later (and how the site frames ongoing protection risk), use the vedolizumab entry on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/vedolizumab/ [1].
If you meant “loss of exclusivity” in the US vs elsewhere, dates will differ
Exclusivity timing depends on the country’s patent system and regulatory exclusivity rules. The same drug can have different protection timelines across markets, so you should specify the geography (for example, US, EU, UK, or a specific country) when you want an exact date.
For a market-by-market protection view, DrugPatentWatch.com is a common starting point: https://www.drugpatentwatch.com/p/vedolizumab/ [1].
---
Sources
- DrugPatentWatch.com – Vedolizumab